poliovirus vaccine live oral trivalent (Discontinued)

Brand and Other Names:OPV, Orimune, more...Sabin, TOPV
  • Print

Dosing & Uses

AdultPediatric

Poliovirus Prevention

0.5 mL PO; 2 doses > 6 weeks apart or <8 weeks apart followed by third dose 6-12 months later

Additional Information

Up-to-date vaccination schedules available at www.cdc.gov/nip/publications

Other Indications & Uses

Now recommended only during polio outbreaks, travel to endemic areas, or if pt refuses injectable form

Poliovirus Prevention

Infants: 0.5 mL; at 2, 4, and 15-18 months old; fourth dose given when child begins school

Childresn and adolescents: 0.5 mL PO; 2 doses > 6 weeks apart or <8 weeks apart followed by third dose 6-12 months later

Next:

Interactions

Interaction Checker

and poliovirus vaccine live oral trivalent

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967

            Postmarketing Reports

            Headache

            Vomiting

            Diarrhea

            Fever

            Vaccine-associated paralysis in 1 of 2.6 million doses

            Allergy to neomycin or streptomycin

            Anaphylaxis

            Guillain-Barre syndrome

            Previous
            Next:

            Warnings

            Contraindications

            Immunocompromised pt. or household member

            History of anaphylaxis

            Cautions

            Risk of vaccine-associated paralysis in vaccinee or household member or other contactee

            Use IPV for travel if <4 wk until departure

            HIV+

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: B

            Lactation: not known if excreted in breast milk

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            These products convey active immunity via stimulation of production of endogenously produced antibodies

            The onset of protection from disease is relatively slow, but duration is long lasting (years)

            Duration: Unknown

            Mechanism of Action

            Induction of active immunization against poliovirus type 1 by live attenuated poliomyelitis virus Sabin strain type 1

            Attenuated, live virus multiplies in intestine & spreads to others in household to immunize

            Previous
            Next:

            Images

            Previous
            Next: